The overactive bladder: Review of current pharmacotherapy in adults. Part 1: Pathophysiology and anticholinergic therapy

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 5, 2006, Pages 509-527

  Sahai, Arun ^a   Khan, Mohammed Shamim ^a   Arya, Manit ^b   John, Jason ^a   Singh, Rajinder ^a   Patel, Hitendra R H ^b  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Darifenacin; Detrusor overactivity; Health related quality of life; Overactive bladder; Oxybutynin; Propiverine; Solifenacin; Tolterodine; Trospium chloride

Indexed keywords

BOTULINUM TOXIN; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; OXYBUTYNIN; PLACEBO; PROPIVERINE; RESINIFERATOXIN; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ACCOMMODATION DISORDER; ANAMNESIS; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; GASTROESOPHAGEAL REFLUX; HEALTH CARE PLANNING; HEALTH ECONOMICS; HUMAN; LIFESTYLE; META ANALYSIS; MICTURITION; MORBIDITY; NOCTURIA; NONHUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; QUALITY OF LIFE; REVIEW; SUSTAINED DRUG RELEASE; SYSTEMATIC REVIEW; TACHYCARDIA; TREATMENT FAILURE; URGE INCONTINENCE; URINARY FREQUENCY; URINARY URGENCY; URINE RETENTION; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVESICAL; ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; BENZHYDRYL COMPOUNDS; BENZILATES; CHOLINERGIC ANTAGONISTS; CRESOLS; DELAYED-ACTION PREPARATIONS; HUMANS; MANDELIC ACIDS; MODELS, ANIMAL; PHENYLPROPANOLAMINE; PRACTICE GUIDELINES; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE;

EID: 33645829573     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.5.509     Document Type: Review

References (146)

1. ABRAMS P, CARDOZO L, FALL M et al.: Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. (2002) 21(2):167-178.
2. MILSOM I, ABRAMS P, CARDOZO L et al.: How widespread are the symptoms of the overactive bladder and how are they managed? A population based prevalence study. BJU Int. (2001) 87(9):760-766.
3. STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20(6):327-336.
4. KEANE DP, O'SULLIVAN S: Urinary incontinence: anatomy, physiology and pathophysiology. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol. (2000) 14(2):207-226.
5. HU TW, WAGNER TH, BENTKOVER JD et al.: Estimated economic costs of overactive bladder in the United States. Urology (2003) 61(6):1123-8.
6. STEWART WF, VAN ROOYEN JB, CUNDIFF GW et al.: Prevalence and burden of overactive bladder in the United States. World J. Urol. (2003) 20(6):327-336.
7. KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A new questionnaire to assess the quality of life of urinary incontinent women. Br. J. Obstet. Gynaecol. (1997) 104:1374-1379.
8. BROWN JS, MCGHAN WF, CHOKROVERY S: Comorbidities associated with overactive bladder. Am. J. Manage. Care (2000) 6(Suppl.):S574-S579.
9. DE GROAT WC: A neurologic basis for the overactive bladder. Urology (1997) 50(Suppl. 6A):36-52.
10. SCHNEIDER T, FETSCHER C, KREGE S, MICHEL MC: Signal transduction underlying carbachol-induced contraction of human urinary bladder. J. Pharmacol. Exp. Ther. (2004) 309(3):1148-1153.
11. CHESS-WILLIAMS R, CHAPPLE CR, YAMANISHI T, SELLERS SJ: The minor population of M3 receptors mediate contraction of human detrusor muscle in vitro. J. Auton. Pharmacol. (2002) 21(5-6):243-248.
12. WANG P, LUTHIN GR, RUGGIERI MR: Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J. Pharmacol. Exp. Ther. (1995) 273:959-966.
13. HEGDE SS, CHOPPIN A, BONHAUS D et al.: Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br. J. Pharmacol. (1997) 120:1409-1418.
14. BRAVERMAN AS, LUTHIN GR, RUGGIERI MR: M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am. J. Physiol. (1998) 275(5 Pt. 2):R1654-R1660.
15. SOMOGYI GT, DE GROAT WC: Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci. (1999) 64(6-7):411-418.
16. CHANCELLOR MB, YOSHIMURA N: Part V: physiology and pharmacology of the bladder and urethra. In: Campbell's Urology Vol 2. 8th edn. Walsh PC, Retik AB, Vaughn ED Jr, Wein AJ (Eds). WB Saunders, Philadelphia (2002):831-886.
17. MORRISON JFB: Sensations arising from the lower urinary tract. In: The physiology of the lower urinary tract. Torrens M, Morrison JFB (Eds). Berlin, Springer-Verlag (1987):89-131.
18. DIXON JS, GILPIN CJ: Presumptive sensory axons of the human urinary bladder: a fine structural study. J. Anat. (1987) 151:199-207.
19. GABELLA G, DAVIS C: Distribution of afferent axons in the bladder of rats. J. Neurocytol. (1998) 27(3):141-155.
20. IGGO A: Tension receptors in the stomach and the urinary bladder. J. Physiol. (1955) 128(3):593-607.
21. FLOYD K, HICK VE, MORRISON JF: Mechanosensitive afferent units in the hypogastric nerve of the cat. J. Physiol. (1976) 259(2):457-471.
22. MORRISON J: The activation of bladder wall afferent nerves. Exp. Physiol. (1999) 84(1):131-136.
23. SJOGREN C, ANDERSSON KE, HUSTED S, MATTIASSON A, MOLLER-MADSEN B: Atropine resistance of transmurally stimulated isolated human bladder muscle. J. Urol. (1982) 128(6):1368-1371.
24. SIBLEY GN: A comparison of spontaneous and nerve-mediated activity in bladder muscle from man, pig and rabbit. J. Physiol. (1984) 354:431-443.
25. BAYLISS M, WU C, NEWGREEN D, MUNDY AR, FRY CH: A quantitative study of atropine-resistant contractile responses in human detrusor smooth muscle, from stable, unstable and obstructed bladders. J. Urol. (1999) 162(5):1833-1839.
26. O'REILLY BA, KOSAKA AH, CHANG TK et al.: A quantitative analysis of purinoceptor expression in human fetal and adult bladders. J. Urol. (2001) 165(5):1730-1734.
27. O'REILLY BA, KOSAKA AH, KNIGHT GF et al.: P2X receptors and their role in female idiopathic detrusor instability. J. Urol. (2002) 167(1):157-164.
28. O'REILLY BA, KOSAKA AH, CHANG TK, FORD AP, POPERT R, MCMAHON SB: A quantitative analysis of purinoceptor expression in the bladders of patients with symptomatic outlet obstruction. BJU Int. (2001) 87(7):617-622.
29. ANDERSSON KE, HEDLUND P: Pharmacological perspective on the physiology of the lower urinary tract. Urology (2002) 60(Suppl. 5A):13-21.
30. HABLER HJ, JANIG W, KOLTZENBURG M: Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J. Physiol. (1990) 425:545-562.
31. DE GROAT WC, KAWATANI M, HISAMITSU T et al.: Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J. Auton. Nerv. Syst. (1990) 30(Suppl.):S71-77.
32. RONG W, SPYER KM, BURNSTOCK G: Activation and sensitisation of low and high threshold afferent fibres mediated by P2X receptors in the mouse urinary bladder. J. Physiol. (2002) 541(Pt. 2):591-600.
33. SMET PJ, MOORE KH, JONAVICIUS J: Distribution and co-localisation of calcitonin gene-related peptide, tachykinins, and vasoactive intestinal peptide in normal and idiopathic unstable urinary bladder. Lab. Invest. (1997) 77(1):37-49.
34. BRADING AF: A myogenic basis for the overactive bladder. Urology (1997) 50(Suppl. 6A):57-67.
35. GOSLING JA, GILPIN SA, DIXON JS, GILPIN CJ: Decrease in the autonomic innervation of human detrusor muscle in outflow obstruction. J. Urol. (1986) 136(2):501-504.
36. MILLS IW, GREENLAND JE, MCMURRAY G et al.: Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J. Urol. (2000) 163(2):646-651.
37. CHARLTON RG, MORLEY AR, CHAMBERS P, GILLESPIE JI: Focal changes in nerve, muscle and connective tissue in normal and unstable human bladder. BJU Int. (1999) 84(9):953-960.
38. SIBLEY GNA: Developments in our understanding of detrusor instability. Br. J. Urol. (1997) 80(Suppl. 1):54-61.
39. STEERS WD: Pathophysiology of overactive bladder and urge urinary incontinence. Rev. Urol. (2002) 4(Suppl. 4):S7-S18.
40. ELBADAWI A, YALLA SV, RESNICK NM: Structural basis of geriatric voiding dysfunction. III. Detrusor overactivity. J. Urol. (1993) 150(5 Pt. 2):1668-1680.
41. DRAKE MJ, HARVEY IJ, GILLESPIE JI: Autonomous activity in the isolated guinea pig bladder. Exp. Physiol. (2003) 88:19-30.
42. DRAKE MJ, MILLS IW, GILLESPIE JI: Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet (2001) 358:401-403.
43. GILLESPIE JI: The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int. (2004) 93(4):478-483.
44. FANTL JA, WYMAN JF, MCCLISH DK et al.: Efficacy of bladder training in older women with urinary incontinence. JAMA (1991) 265:609-613.
45. HERBISON P, HAY-SMITH J, ELLIS G, MOORE K: Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. Br. Med. J. (2003) 326(7394):841-844.
46. MADERSBACHER H: Overactive bladder: a clinical entity or a marketing hype? Eur. Urol. (2005) 47(3):273-276.
47. CHAPPLE C, KHULLAR V, GABRIEL Z, DOOLEY JA: The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur. Urol. (2005) 48(1):5-26.
48. THOMPSON IM, LAUVETZ R: Oxybutynin in bladder spasm, neurogenic bladder and enuresis. Urology (1976) 8:452.
49. HUGGINS ME, BHATIA NN, OSTERGARD DR: Urinary incontinence: newer pharmacotherapeutic trends. Curr. Opin. Obstet. Gynaecol. (2003) 15:419-427.
50. NILVEBRANT L, ANDERSON KE, GILLBERG PG, STAHL M, SPARF B: Tolterodine-a new bladder-selective antimuscarinic agent. Eur. J. Pharmacol. (1997) 327(2-3):195-207.
51. ABRAMS P, FREEMAN R, ANDERSTROM C, MATTIASSON A: Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. (1998) 81(6):801-810.
52. BURGIO KL, LOCHER JL, GOODE PS et al.: Behavioral versus drug treatment for urge urinary incontinence in older women: a randomised controlled trial. JAMA (1998) 280(23):1995-2000.
53. DRUTZ HP, APPELL RA, GLEASON D, KLIMBERG I, RADOMSKI S: Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int. Urogynecol. J. Pelvic Floor Dysfunct. (1999) 10(5):283-289.
54. MADERSBACHER H, HALASKA M, VOIGT R, ALLOUSSI S, HOFNER K: A placebo-controlled, multicenter study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. (1999) 84(6):646-651.
55. THUROFF JW, BUNKE B, EBNER A et al.: Randomised, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol. (1991) 145(4):813-817.
56. MOORE KH, HAY DM, IMRIE AE, WATSON A, GOLDSTEIN M: Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Br. J. Urol. (1990) 66(5):479-485.
57. TAPP AJ, CARDOZO LD, VERSI E, COOPER D: The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study. Br. J. Obstet. Gynaecol. (1990) 97(6):521-526.
58. HOMMA Y, PAICK JS, LEE JG, KAWABE K, JAPANESE AND KOREAN TOLTERODINE STUDY GROUP: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in Japanese and Korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. (2003) 92(7):741-747.
59. GUPTA SK, SATHYAN G: Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J. Clin. Pharmacol. (1999) 39(3):289-296.
60. OUSLANDER JG: Drug therapy: management of overactive bladder. N. Engl. J. Med. (2004) 350(8):786-799.
61. KELLEHER CJ, CARDOZO LD, KHULLAR V, SALVATORE S: A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br. J. Obstet. Gynaecol. (1997) 104(9):988-993.
62. NYGAARD IE, KREDER KJ: Pharmacologic therapy of lower urinary tract dysfunction. Clin. Obstet. Gynaecol. (2004) 47(1):83-92.
63. GLEASON DM, SUSSET J, WHITE C, MUNOZ DR, SAND PK: Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group. Urology (1999) 54(3):420-423.
64. VERSI E, APPELL R, MOBLEY D, PATTON W, SALTZSTEIN D: Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet. Gynecol. (2000) 95(5):718-721.
65. ANDERSON RU, MOBLEY D, BLANK B, SALTZSTEIN D, SUSSET J, BROWN JS: Once daily controlled versus IR oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J. Urol. (1999) 161(6):1809-1812.
66. BIRNS J, LUKKARI E, MALONE-LEE JG: A randomized controlled trial comparing the efficacy of controlled-release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin. BJU Int. (2000) 85(7):793-798.
67. BARKIN J, CORCOS J, RADOMSKI S et al.: A randomized, double-blind, parallel-group comparison of controlled- and immediate-release oxybutynin chloride in urge urinary incontinence. Clin. Ther. (2004) 26(7):1026-1036.
68. O'LEARY M, ERICKSON JR, SMITH CP, MCDERMOTT C, HORTON J, CHANCELLOR MB: Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J. Spinal Cord Med. (2003) 26(2):159-162.
69. DIOKNO A, SAND P, LABASKY R et al.: Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int. Urol. Nephrol. (2002) 34(1):43-49.
70. APPELL RA, SAND P, DMOCHOWSKI R et al.: Overactive Bladder: Judging Effective Control and Treatment Study Group. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin. Proc. (2001) 76(4):358-363
71. SAND PK, MIKLOS J, RITTER H, APPELL R: A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int. Urogynecol. J. Pelvic Floor Dysfunct. (2004) 15(4):243-248.
72. NILVEBRANT L, HALLEN B, LARSSON G: Tolterodine - a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. (1997) 60(13-14):1129-1136.
73. OLSSON B, SZAMOSI J: Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus IR tolterodine. Clin. Pharmacokinet. (2001) 40(3):227-235.
74. APPELL RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology (1997) 50(6A Suppl.):90-99.
75. RENTZHOG L, STANTON SL, CARDOZO L, NELSON E, FALL M, ABRAMS P: Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study. Br. J. Urol. (1998) 81(1):42-48.
76. MICHEL MC, DE LA ROSETTE JJ, PIRO M, GOEPEL M: Does concomitant stress incontinence alter the efficacy of tolterodine in patients with overactive bladder? J. Urol. (2004) 172(2):601-604.
77. MALONE-LEE JG, WALSH JB, MAUGOURD MF: Tolterodine: a safe and effective treatment for older patients with overactive bladder. J. Am. Geriatr. Soc. (2001) 49(6):700-705.
78. MILLARD R, TUTTLE J, MOORE K et al.: Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. J. Urol. (1999) 161(5):1551-1555.
79. JACQUETIN B, WYNDAELE J: Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. Eur. J. Obstet. Gynecol. Reprod. Biol. (2001) 98(1):97-102.
80. VAN KERREBROECK P, KREDER K, JONAS U, ZINNER N, WEIN A, TOLTERODINE STUDY GROUP: Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology (2001) 57(3):414-421.
81. ZINNER NR, MATTIASSON A, STANTON SL: Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J. Am. Geriatr. Soc. (2002) 50(5):799-807.
82. KREDER K, MAYNE C, JONAS U: Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur. Urol. (2002) 41(6):588-595.
83. KELLEHER CJ, REESE PR, PLEIL AM, OKANO GJ: Health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag Care (2002) 8(19 Suppl.):S608-S615.
84. KELLEHER CJ, KREDER KJ, PLEIL AM, BURGESS SM, REESE PR: Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am. J. Manag. Care (2002) 809 Suppl.):S616-S630.
85. LANDIS JR, KAPLAN S, SWIFT S, VERSI E: Efficacy of antimuscarinic therapy for overactive bladder with varying degrees of incontinence severity. J. Urol. (2004) 171(2 Pt. 1):752-756.
86. KHULLAR V, HILL S, LAVAL KU, SCHIOTZ HA, JONAS U, VERSI E: Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomised, placebo-controlled trial. Urology (2004) 64(2):269-275.
87. MICHEL MC, DE LA ROSETTE JJ, PIRO M, SCHNEIDER T: Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur. Urol. (2005) 48(1):110-115.
88. HOMMA Y, PAICK JS, LEE JG, KAWABE K, JAPANESE AND KOREAN TOLTERODINE STUDY GROUP: Clinical efficacy and tolerability of extended-release tolterodine and immediate-release oxybutynin in japanese and korean patients with an overactive bladder: a randomized, placebo-controlled trial. BJU Int. (2003) 92(7):741-747.
89. HOMMA Y, KAWABE K: Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomised, placebo-controlled trial. World J. Urol. (2004) 22(4):251-256.
90. TAKEI M, HOMMA Y, THE JAPANESE TOLTERODINE STUDY GROUP: Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients. Int. J. Urol. (2005) 12(5):456-464.
91. DIOKNO AC, APPELL RA, SAND PK et al.: OPERA Study Group. Prospective, randomised, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin. Proc. (2003) 78(6):687-695.
92. SUSSMAN D, GARELY A: Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the antimuscarinic clinical effectiveness trial (ACET). Curr. Med. Res. Opin. (2002) 18(4):177-184.
93. HUGHES DA, DUBOIS D: Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics (2004) 22(16):1047-1059.
94. MADERSBACHER H, HALASKA M, VOIGT R, ALLOUSSI S, HOFNER K: A placebo-controlled, multicenter study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence. BJU Int. (1999) 84(6):646-651.
95. MAZUR D, WEHNERT J, DORSCHNER W, SCHUBERT G, HERFURTH G, ALKEN RG: Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicenter dose-optimising study. Scand J. Urol. Nephrol (1995) 29(3):289-294.
96. STOHRER M, MADERSBACHER H, RICHTER R, WEHNERT J, DREIKORN K: Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia-a double-blind, placebo-controlled clinical trial. Spinal Cord (1999) 37(3):196-200.
97. DORSCHNER W, STOLZENBURG JU, GRIEBENOW R et al.: Efficacy and cardiac safety of propiverine in elderly patients - a double-blind, placebo-controlled clinical study. Eur. Urol. (2000) 37(6):702-708.
98. JUNEMANN KP, HALASKA M, RITTSTEIN T et al.: Efficacy and tolerability in patients with overactive bladder. Eur. Urol. (2005) 48(3):478-482.
99. TODOROVA A, VONDERHEID-GUTH B, DIMPFEL W: Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. (2001) 41(6):636-644.
100. SINGH-FRANCO D, MACHADO C, TUTEJA S, ZAPANTIS A: Trospium chloride for the treatment of overactive bladder with urge incontinence. Clin. Ther. (2005) 27(5):511-530.
101. STOHRER M, BAUER P, GIANNETTI BM, RICHTER R, BURGDORFER H, MURTZ G: Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicenter placebo-controlled double-blind trial. Urol. Int. (1991) 47(3):138-143.
102. ALLOUSSI S, LAVAL K-U, ECKERT R et al.: A double-blind, randomised, multicenter, placebo-controlled study. J. Drug Assess. (1999) 2:27-39.
103. CARDOZO L, CHAPPLE CR, TOOZS-HOBSON P et al.: Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomised, double-blind, multicenter clinical trial. BJU Int. (2000) 85(6):659-664.
104. ZINNER N, GITTELMAN M, HARRIS R, SUSSET J, KANELOS A, AUERBACH S: Trospium Study Group. Trospium chloride improves overactive bladder symptoms: a multicenter Phase III trial. J. Urol. (2004) 171(6 Pt 1):2311-2315.
105. MADERSBACHER H, STOHRER M, RICHTER R, BURGDORFER H, HACHEN HJ, MURTZ G: Trospium chloride versus oxybutynin: a randomised, double-blind, multicenter trial in the treatment of detrusor hyper-reflexia. Br. J. Urol. (1995) 75(4):452-456.
106. HALASKA M, RALPH G, WIEDEMANN A et al.: Controlled, double-blind, multicenter clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J. Urol. (2003) 20(6):392-399.
107. SMULDERS RA, KRAUWINKEL WJ, SWART PJ, HUANG M: Pharmacokinetics and safety of solifenacin succinate in healthy young men. J. Clin. Pharmacol. (2004) 44(9):1023-1033.
108. KOBAYASHI S, IKEDA K, MIYATA K: Comparison of in vitro selectivity profiles of solifenacin succinate (YM905) and current antimuscarinic drugs in bladder and salivary glands: a Ca2+ mobilisation study in monkey cells. Life Sci. (2004) 74(7):843-853.
109. OHTAKE A, UKAI M, HATANAKA T et al.: In vitro and in vivo tissue selectivity profile of solifenacin succinate (YM905) for urinary bladder over salivary gland in rats. Eur. J. Pharmacol. (2004) 492(2-3):243-250.
110. CHAPPLE CR, ARANO P, BOSCH JL, DE RIDDER D, KRAMER AE, RIDDER AM: Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled Phase II dose-finding study. BJU Int. (2004) 93(1):71-77.
111. CHAPPLE CR, RECHBERGER T, AL-SHUKRI S et al.: YM-905 Study Group. Randomised, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. (2004) 93(3):303-310.
112. CARDOZO L, LISEC M, MILLARD R et al.: Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J. Urol. (2004) 172(5 Pt. 1):1919-1924.
113. HAAB F, CARDOZO L, CHAPPLE C, RIDDER AM, FOR THE SOLIFENACIN STUDY GROUP: Long-term open-label solifnacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur. Urol. (2005) 47:376-384.
114. KELLEHER CJ, CARDOZO L, CHAPPLE CR, HAAB F, RIDDER AM: Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int. (2005) 95(1):81-85.
115. CARDOZO L, CASTRO-DIAZ D, GITTELMAN M, RIDDER A, HUANG M: Reductions in overactive bladder-related incontinence from pooled analysis of Phase III trials evaluating treatment with solifenacin. Int. Urogynaecol J. Pelvic Dysfunct. In press.
116. ABRAMS P, SWIFT S: Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis. Eur. Urol. (2005) 48(3):483-487.
117. KELLEHER C, CARDOZO L, KOBASHI K, LUCENTE V: Solifenacin: as effective in mixed urinary incontinence as in urge urinary incontinence. Int. Urogynecol J. Pelvic Floor Dysfunct. (2005) [Epub ahead of print].
118. CHAPPLE CR, MARTINEZ-GARCIA R, SELVAGGI L et al.: A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR Trial. Eur. Urol. (2005) 48(3):483-487.
119. NAPIER C, GUPTA P: Darifenacin is selective for the human recombinant M3 receptor subtype. Neurourol. Urodyn. (2002) 21: A445.
120. SMULDERS RA, TAN HT, KRAUWINKEL W et al.: A placebo controlled, dose-rising study in healthy male volunteers to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of YM905. Neurourol. Urodyn. (2002) 21(4):297-298.
121. BEAUMONT KC, CUSSANS NJ, NICHOLS DJ, SMITH DA: Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica (1998) 28(1):63-75.
122. CHAPPLE C, STEERS W, NORTON P et al.: A pooled analysis of three Phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int. (2005) 95(7):993-1001.
123. FOOTE J, GLAVIND K, KRALIDIS G, WYNDAELE JJ: Treatment of overactive bladder in the older patient: pooled analysis of three Phase III studies of darifenacin, an M(3) selective receptor antagonist. Eur. Urol. (2005) 48(3):471-477.
124. ANDERSSON K-E: Potential benefits of muscarinic M3 receptor selectivity. Eur. Urol. Suppl. (2002) 1(4):23-28.
125. HAAB F, STEWART L, DWYER P: Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur. Urol. (2004) 45(4):420-429.
126. HILL S, KHULLAR V, WYNDAELE JJ, LHERITIER K: Dose response with darifenacin, a novel once-daily M(3) selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study. Int. Urogynecol. J. Pelvic Floor Dysfunct. (2005) [Epub ahead of print].
127. CHAPPLE CR, ABRAMS P: Comparison of darifenacin and oxybutynin in patients with overactive bladder: assessment of ambulatory urodynamics and impact on salivary flow. Eur. Urol. (2005) 48(1):102-109.
128. ZINNER N, TUTTLE J, MARKS L: Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (m3 sra), compared with oxybutynin in the treatment of patients with overactive bladder. World J. Urol. (2005) 23(4):248-252.
129. BRENDLER CB, RADEBAUGH LC, MOHLER JL: Topical oxybutynin chloride for relaxation of dysfunctional bladders. J. Urol. (1989) 141(6):1350-1352.
130. WEESE DL, ROSKAMP DA, LEACH GE, ZIMMERN PE: Intravesical oxybutynin chloride: experience with 42 patients. Urology (1993) 41(6):527-530.
131. MADERSBACHER H, JILG G: Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride. Paraplegia (1991) 29(2):84-90.
132. PRASAD KV, VAIDYANATHAN S: Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity. Br. J. Urol. (1993) 72(5 Pt. 2):719-722.
133. MIZUNAGA M, MIYATA M, KANEKO S, YACHIKU S, CHIBA K: Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder. Paraplegia (1994) 32(1):25-29.
134. O'FLYNN KJ, THOMAS DG: Intravesical instillation of oxybutynin hydrochloride for detrusor hyper-reflexia. Br. J. Urol. (1993) 72(5 Pt. 1):566-570.
135. PANNEK J, SOMMERFELD HJ, BOTEL U, SENGE T: Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology (2000) 55(3):358-362.
136. ENZELSBERGER H, HELMER H, KURZ C: Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br. J. Obstet. Gynaecol. (1995) 102(11):929-930.
137. LEHTORANTA K, TAINIO H, LUKKARI-LAX E, HAKONEN T, TAMMELA TL: Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity. Scand. J. Urol. Nephrol. (2002) 36(1):18-24.
138. SAITO M, WATANABE T, TABUCHI F, OTSUBO K, SATOH K, MIYAGAWA I: Urodynamic effects and safety of modified intravesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int. J. Urol. (2004) 11(8):592-596.
139. KASABIAN NG, VLACHIOTIS JD, LAIS A et al.: The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia. J. Urol. (1994) 151(4):944-945.
140. APPELL RA, CHANCELLOR MB, ZOBRIST RH, THOMAS H, SANDERS SW: Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc. (2003) 78(6):696-702.
141. DAVILA GW, DAUGHERTY CA, SANDERS SW: A short-term, multicenter, randomised double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J. Urol. (2001) 166(1):140-145.
142. DMOCHOWSKI RR, DAVILA GW, ZINNER NR et al.: Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J. Urol. (2002) 168(2):580-586.
143. DMOCHOWSKI RR, SAND PK, ZINNER NR, GITTELMAN MC, DAVILA GW, SANDERS SW: Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology (2003) 62(2):237-242.
144. RICCI JA, BAGGISH JS, HUNT TL et al.: Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin. Ther. (2001) 23(8):1245-1259.
145. GOUGH DCS: Enterocystoplasty. BJU Int. (2001) 88:739-743.
146. THUROFF J, ABRAMS P, ANDERSSON KE et al.: Guidelines on Urinary Incontinence. In: EAU Guidelines Pocket Edition 3. European Association of Urology (2005).